Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | ACACA | Q13085 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17063239 | 0.86 | CHRNB2 (0.44) | ACHEF2KDM4E | |
| SCHEMBL17063251 | 0.84 | NAMPT (0.43) | HTR2BBRD4NAMPTACACBACACA | |
| SCHEMBL17069458 | 0.83 | ROCK2 (0.42) | HTR2BBRD4NAMPTACHEKDM4E | |
| SCHEMBL17063383 | 0.80 | KDM4E (0.46) | BRD4NAMPTACHEF2KDM4E | |
| SCHEMBL19461585 | 0.78 | JAK1 (0.44) | HTR2BBRD4NAMPTACACBACACA | |
| SCHEMBL17063332 | 0.76 | KDM4E (0.44) | NAMPTACHEF2KDM4E | |
| SCHEMBL19461813 | 0.75 | JAK1 (0.42) | HTR2BNAMPTACACBACACACHEK2 | |
| SCHEMBL17462971 | 0.74 | NAMPT (0.44) | HTR2BBRD4NAMPTACACBACACA | |
| SCHEMBL19461752 | 0.74 | JAK1 (0.45) | HTR2BNAMPTACACBACACACHEK2 | |
| SCHEMBL17063311 | 0.74 | RXRA (0.42) | HTR2BBRD4NAMPTACHEF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3116504-A2 | RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | Innov17 LLC (US) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015138276-A2 | RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC (US) | 2015-09-17 | — | — | WO | disclosed |
| US-20150252022-A1 | RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252022-A1 | RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | RARA, RARB, RARG | HTR2B 3071/4885BRD4 4543/4885NAMPT 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.